We are analyzing https://link.springer.com/article/10.1186/bcr1796.

Title:
Breast tumour angiogenesis | Breast Cancer Research
Description:
The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

pubmed, cancer, breast, google, scholar, cas, article, tumour, growth, angiogenesis, factor, endothelial, vascular, cells, cell, vegf, human, angiogenic, patients, res, central, expression, receptor, harris, tumours, antiangiogenic, bevacizumab, vegfr, agents, hif, tumor, response, fox, neovascularization, blood, treatment, cancers, clin, therapy, trial, including, clinical, phase, hypoxiainducible, hifα, pathway, factors, hypoxia, metastatic, proliferation,

Topics {✒️}

bone-marrow-derived endothelial cells bone-marrow-derived endothelial bone marrow-derived cells diffusible tumour-derived factor von hippel-lindau protein hypoxia-inducible factor 1alpha transforming growth factor-β1 triazine-n-oxide derivatives hypoxia-inducible factor 1α hypoxia-inducible factor-2 alpha node-positive breast cancer von hippel-lindau widespread hypoxia-inducible expression hif-induced gene expression isoform-specific receptors neuropilin-1 activator cbp/p300 led c-fos receptor tki stromal-derived factor 1 protracted low-dose chemotherapy augment neo-vessel formation platelet/megakaryocyte lineages tumour necrosis factor-α low-dose oral methotrexate transforming growth factor tam hif-2α expression receptor tyrosine kinases fibroblast growth factor dose-limiting side effects breast cancer hif-2α hypoxia-inducible factor hypoxia-inducible factor 1 hypoxia inducible factor circulating endothelial precursors breast research laboratory endothelial progenitor cells placenta growth factor vascular endothelial cells endothelial cell proliferation block hif-1α expression growth-factor pathways oxygen-dependent degradation domain cytokine-mediated pathways provide low oxygen microenvironment cancer research uk tyrosine kinase portion mobilizes precursor cells attenuates vegf-mediated angiogenesis recent translational research vegf-induced adult neovascularization median progression-free survival

Questions {❓}

McDonald DM, Munn L, Jain RK: Vasculogenic mimicry: how convincing, how novel, and how significant?
Miller KD: Recent translational research: antiangiogenic therapy for breast cancer: where do we stand?
Ratcliffe PJ: HIF-1 and HIF-2: working alone or together in hypoxia?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Breast tumour angiogenesis
         description:The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.
         datePublished:2007-12-18T00:00:00Z
         dateModified:2007-12-18T00:00:00Z
         pageStart:1
         pageEnd:11
         sameAs:https://doi.org/10.1186/bcr1796
         keywords:
            Breast Cancer
            Bevacizumab
            Sorafenib
            Angiogenic Factor
            Inflammatory Breast Cancer
            Cancer Research
            Oncology
            Surgical Oncology
         image:
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:9
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Stephen B Fox
               affiliation:
                     name:Peter MacCallum Cancer Centre
                     address:
                        name:Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Daniele G Generali
               affiliation:
                     name:Istituti Ospitalieri di Cremona, Viale Concordia
                     address:
                        name:Unità di Patologia Mammaria, Senology and Breast Cancer Unit, Breast Research Laboratory, Istituti Ospitalieri di Cremona, Viale Concordia, Cremona, Italy
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adrian L Harris
               affiliation:
                     name:John Radcliffe Hospital
                     address:
                        name:Molecular Oncology, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Breast tumour angiogenesis
      description:The central importance of tumour neovascularization has been emphasized by clinical trials using antiangiogenic therapy in breast cancer. This review gives a background to breast tumour neovascularization in in situ and invasive breast cancer, outlines the mechanisms by which this is achieved and discusses the influence of the microenvironment, focusing on hypoxia. The regulation of angiogenesis and the antivascular agents that are used in an antiangiogenic dosing schedule, both novel and conventional, are also summarized.
      datePublished:2007-12-18T00:00:00Z
      dateModified:2007-12-18T00:00:00Z
      pageStart:1
      pageEnd:11
      sameAs:https://doi.org/10.1186/bcr1796
      keywords:
         Breast Cancer
         Bevacizumab
         Sorafenib
         Angiogenic Factor
         Inflammatory Breast Cancer
         Cancer Research
         Oncology
         Surgical Oncology
      image:
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:9
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Stephen B Fox
            affiliation:
                  name:Peter MacCallum Cancer Centre
                  address:
                     name:Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Daniele G Generali
            affiliation:
                  name:Istituti Ospitalieri di Cremona, Viale Concordia
                  address:
                     name:Unità di Patologia Mammaria, Senology and Breast Cancer Unit, Breast Research Laboratory, Istituti Ospitalieri di Cremona, Viale Concordia, Cremona, Italy
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adrian L Harris
            affiliation:
                  name:John Radcliffe Hospital
                  address:
                     name:Molecular Oncology, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:9
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Peter MacCallum Cancer Centre
      address:
         name:Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
         type:PostalAddress
      name:Istituti Ospitalieri di Cremona, Viale Concordia
      address:
         name:Unità di Patologia Mammaria, Senology and Breast Cancer Unit, Breast Research Laboratory, Istituti Ospitalieri di Cremona, Viale Concordia, Cremona, Italy
         type:PostalAddress
      name:John Radcliffe Hospital
      address:
         name:Molecular Oncology, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Stephen B Fox
      affiliation:
            name:Peter MacCallum Cancer Centre
            address:
               name:Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Daniele G Generali
      affiliation:
            name:Istituti Ospitalieri di Cremona, Viale Concordia
            address:
               name:Unità di Patologia Mammaria, Senology and Breast Cancer Unit, Breast Research Laboratory, Istituti Ospitalieri di Cremona, Viale Concordia, Cremona, Italy
               type:PostalAddress
            type:Organization
      name:Adrian L Harris
      affiliation:
            name:John Radcliffe Hospital
            address:
               name:Molecular Oncology, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Pathology, Peter MacCallum Cancer Centre, East Melbourne, Australia
      name:Unità di Patologia Mammaria, Senology and Breast Cancer Unit, Breast Research Laboratory, Istituti Ospitalieri di Cremona, Viale Concordia, Cremona, Italy
      name:Molecular Oncology, Cancer Research UK, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, UK

External Links {🔗}(433)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

5.97s.

LINK . SPRINGER . COM {}